HOME >> MEDICINE >> NEWS
Preliminary study shows high-dose coenzyme Q10 slows functional decline in Parkinson's patients

A national clinical trial with 80 Parkinson's disease patients has shown that high dosages of a naturally occurring compound, coenzyme Q10, slowed by 44 percent the progressive deterioration in function that occurs in the disease. The greatest benefit was seen in everyday activities such as feeding, dressing, bathing and walking.

The study's coordinators caution that while encouraging, the therapy needs to be tested in a larger trial with hundreds of patients before this treatment can be recommended.

Published in the Oct. 15, 2002 issue of the American Medical Association's Archives of Neurology, the study was conducted at 10 sites by the Parkinson Study Group, under the direction of principal investigator Clifford Shults, M.D., professor of neurosciences, University of California, San Diego (UCSD) School of Medicine, and chief of the Neurology Service at the VA San Diego Healthcare System. Parkinson's disease is a degenerative disorder of the brain in which patients develop tremor, slowness of movement and stiffness of muscles. It affects approximately 1 percent of Americans over the age of 65. Although certain drugs, such as levodopa, can reduce the symptoms of Parkinson's disease, no treatment has been shown to slow the progressive deterioration in function.

The selection of coenzyme Q10 as a potential treatment for Parkinson's was based on work carried out over the past decade by Shults, Richard Haas, M.D., UCSD professor of neurosciences, and Flint Beal, M.D., professor and chair of neurology, Weill Medical College of Cornell University.

Shults explained that mitochondria produce the energy-containing molecules that supply energy to chemical reactions in cells and that coenzyme Q10 plays an integral role in that process. He further explained that coenzyme Q10 is also a potent antioxidant. Over the past several years, research by Shults, Haas and Beal showed that mitochondrial function is impaired in patients with Park
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2002


Page: 1 2 3 4

Related medicine news :

1. Preliminary results are promising in Alzheimers gene therapy trial
2. Preliminary report suggests combination therapy may help treat SARS
3. Preliminary study finds stem cells in blood restore damaged heart muscle
4. Preliminary study suggests endomitriosis could contribute to infertility
5. Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
6. Preliminary Study Proves Centuries Of Herbalists Right About Echinacea
7. ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function
8. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
9. UMaine study looks at infants and chronic nighttime crying
10. Chronic pain treatments more effective when taken together, new study shows
11. UNC study: Most N.C. family practitioners engage in unrecognized community service

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in ... has been life-saving as she has been on the trial for more than ... with ovarian cancer in 2009. She underwent standard chemotherapy but a year later went ...
(Date:1/20/2017)... ... ... account following a man who went on to support his country and serve the Lord. ... Haven, Florida and at the age of 5, his family moved to Pensacola Florida. In ... and got married right out of boot camp. , He and his wife raised ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a moving and ... God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired truck driver, ... , “I have been writing since high school and have many different titles,” Gaapf ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear ... political games that circumvent health needs of over 30 million. Many interviews with Dr. ... and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, comedic content, ... series that uses humor to highlight ways to improve heart health and overall well-being. ... movement, which is designed to inspire all Americans to make small changes that add ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... -- Entscheidung fällt als Reaktion ... Die internationale humanitäre Stadt soll um knapp 2800 m² erweitert ... Seine Hoheit Scheich Muhammad bin Raschid Al ... Dubai , hat den Auftrag erteilt, ... City IHC) zu verdreifachen, um den Betrieb zur Unterstützung ...
(Date:1/19/2017)... -- Germany Cataract Surgery Devices Market ... "Germany Cataract Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic Devices ... distribution shares data for each of these market segements, ...
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... the Ophthalmic Devices Market? Which areas are going to ... you potential revenues to 2026, assessing data, trends, opportunities ... charts, and graphs. Discover the most lucrative areas in ... study lets you assess forecasted sales across the all ...
Breaking Medicine Technology:
Cached News: